FDA guides on abuse-deterrent opioids; generics direction pending
This article was originally published in Scrip
Executive Summary
The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.